Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders and Castleman Disease

Launched by NATIONAL CANCER INSTITUTE (NCI) · Oct 3, 2017

Keywords

ClinConnect Summary

This clinical trial is looking at how certain viruses and immune system disorders, like HIV and Castleman Disease, are linked to different types of cancer. The researchers want to understand the genetic differences in cancer cells compared to normal cells in order to improve ways to prevent, detect, and treat these cancers. They are specifically interested in cancers that are commonly found in individuals with weakened immune systems.

To participate in this study, you need to be at least 18 years old and have specific types of cancer or immune disorders, such as HIV. Participants will undergo some medical tests, provide tissue samples (which might be collected during routine medical procedures), and their medical history will be reviewed. All samples will be kept for future research without any personal information attached. If you join the trial, you may receive updates about the findings related to your samples. This research is important for better understanding how these types of cancers develop and how they can be treated.

Gender

ALL

Eligibility criteria

• * INCLUSION CRITERIA:
• Patients with one or more of the following:
• • HIV or other acquired immunodeficiency and cancer
• • Viral-associated cancer or cancer hypothesized to be caused by a virus
• • HIV-negative patients with cancer that commonly occurs in people with HIV
• • --KSHV-associated malignancy or related diseases, such as Multicentric Castleman Disease
• • A malignancy hypothesized to be caused by an endogenous retrovirus
• • Idiopathic Castleman disease
• • Cancer diagnoses will be confirmed by the NCI Laboratory of Pathology. A biopsy will be collected if sufficient archival tissue is not available.
• • Age \>=18 years.
• • ECOG performance status \<=2 (Karnofsky \>=60%) if biopsy to be performed is solely for the purposes of this protocol. Any ECOG performance status will be allowed if biopsy required for patient care or another NIH protocol that allows lower performance status or if enrollment on this protocol is only for the purposes of studying tissue that has already been collected.
• • Patients must have signed or be willing to sign an IRB-approved informed consent document that permits the use of the tumor and other samples for genomic-based molecular characterization projects. Telephone consent for use of archival tissue or tissue collected on another protocol or standard patient care will be permitted.
• • Co-enrollment on other HAMB, NCI, or NIH protocols is allowed
• EXCLUSION CRITERIA:
• • Inability to provide informed consent.
• • Pregnancy: Pregnant women will not be allowed to participate in this study because there is not a potential benefit.